|
The Indian Pharmacopoeia Commission (IPC) in collaboration with the Council of Scientific and Industrial Research (CSIR)-Indian Institute of Integrative Medicine (IIIM) will be hosting a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 on April 17, 2026 to strengthen the quality, safety, and regulatory integrity of pharmaceuticals in India.
The conclave is designed to create a unified platform for dialogue, innovation, and strategic alignment among stakeholders in the pharmaceutical sector. The event will be hosted at the Auditorium, CSIR-IIIM, Jammu, bringing together experts and practitioners from across the country in a setting conducive to both learning and collaboration.
At a broader level, the conclave reflects a national commitment to upholding and advancing drug quality standards through the latest edition of the IP 2026. The IP serves as the official benchmark for drug quality in India, outlining specifications, test methods, and acceptance criteria for pharmaceutical substances and products. With evolving global standards, emerging technologies, and increasingly complex formulations, regular updates to the pharmacopoeia are essential. This conclave plays a critical role in communicating those updates effectively.
The event will delve deeply into scientific advancements and regulatory developments that define IP 2026. Participants will gain exposure to updated analytical techniques, modernized testing protocols, and revised monographs that reflect current best practices. In addition, discussions will address regulatory expectations, compliance challenges, and the practical implications of implementing new standards within manufacturing and quality systems.
“What distinguishes this conclave is its interactive and industry-centric approach. Rather than a one-way dissemination of information, the session is structured to encourage active participation, enabling attendees to engage directly with subject-matter experts, clarify technical queries, and share field-level experiences. This exchange of ideas is expected to foster a deeper understanding of pharmacopoeial requirements and promote their consistent application across the industry,” according to an official associated with the development.
The conclave is tailored for a wide spectrum of professionals who contribute to the pharmaceutical value chain. It is especially relevant for pharmaceutical manufacturers, responsible for translating standards into production practices, Quality Control (QC) and Quality Assurance (QA) professionals, ensuring adherence to specifications and regulatory compliance, regulatory affairs experts, interpreting and implementing evolving guidelines, analytical scientists and academicians, advancing research and method development and Non-Governmental Organizations (NGOs), advocating for access to safe and effective medicines.
“By bringing together these diverse groups, the initiative aims to build a cohesive and future-ready ecosystem that prioritizes quality at every stage, from raw material testing to finished product release. It also encourages alignment with international benchmarks, thereby enhancing the global credibility of India’s pharmaceutical sector. It is a strategic effort to strengthen the foundation of public health. By promoting awareness, encouraging collaboration, and facilitating the adoption of updated standards, it contributes to a healthcare system where patients can rely on the safety, efficacy, and consistency of the medicines they receive,” the official added.
|